Mesenchymal stromal cells for the treatment of critical limb ischemia: context and perspective

Cell therapy using mesenchymal stromal cells (MSCs) is a promising new avenue of treatment for critical limb ischemia (CLI). Preclinical studies have suggested that MSCs enhance neovascularization in ischemic limbs. In this commentary, we discuss a recent study by Gupta and colleagues, one of the fi...

Descripción completa

Detalles Bibliográficos
Autores principales: Gremmels, Hendrik, Fledderus, Joost O, Teraa, Martin, Verhaar, Marianne C
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4055075/
https://www.ncbi.nlm.nih.gov/pubmed/24246031
http://dx.doi.org/10.1186/scrt351
_version_ 1782320593142546432
author Gremmels, Hendrik
Fledderus, Joost O
Teraa, Martin
Verhaar, Marianne C
author_facet Gremmels, Hendrik
Fledderus, Joost O
Teraa, Martin
Verhaar, Marianne C
author_sort Gremmels, Hendrik
collection PubMed
description Cell therapy using mesenchymal stromal cells (MSCs) is a promising new avenue of treatment for critical limb ischemia (CLI). Preclinical studies have suggested that MSCs enhance neovascularization in ischemic limbs. In this commentary, we discuss a recent study by Gupta and colleagues, one of the first human trials using allogeneic MSCs for CLI, in relation to the current state of knowledge regarding cell therapy for CLI.
format Online
Article
Text
id pubmed-4055075
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-40550752014-11-18 Mesenchymal stromal cells for the treatment of critical limb ischemia: context and perspective Gremmels, Hendrik Fledderus, Joost O Teraa, Martin Verhaar, Marianne C Stem Cell Res Ther Commentary Cell therapy using mesenchymal stromal cells (MSCs) is a promising new avenue of treatment for critical limb ischemia (CLI). Preclinical studies have suggested that MSCs enhance neovascularization in ischemic limbs. In this commentary, we discuss a recent study by Gupta and colleagues, one of the first human trials using allogeneic MSCs for CLI, in relation to the current state of knowledge regarding cell therapy for CLI. BioMed Central 2013-11-18 /pmc/articles/PMC4055075/ /pubmed/24246031 http://dx.doi.org/10.1186/scrt351 Text en Copyright © 2013 BioMed Central Ltd.
spellingShingle Commentary
Gremmels, Hendrik
Fledderus, Joost O
Teraa, Martin
Verhaar, Marianne C
Mesenchymal stromal cells for the treatment of critical limb ischemia: context and perspective
title Mesenchymal stromal cells for the treatment of critical limb ischemia: context and perspective
title_full Mesenchymal stromal cells for the treatment of critical limb ischemia: context and perspective
title_fullStr Mesenchymal stromal cells for the treatment of critical limb ischemia: context and perspective
title_full_unstemmed Mesenchymal stromal cells for the treatment of critical limb ischemia: context and perspective
title_short Mesenchymal stromal cells for the treatment of critical limb ischemia: context and perspective
title_sort mesenchymal stromal cells for the treatment of critical limb ischemia: context and perspective
topic Commentary
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4055075/
https://www.ncbi.nlm.nih.gov/pubmed/24246031
http://dx.doi.org/10.1186/scrt351
work_keys_str_mv AT gremmelshendrik mesenchymalstromalcellsforthetreatmentofcriticallimbischemiacontextandperspective
AT fledderusjoosto mesenchymalstromalcellsforthetreatmentofcriticallimbischemiacontextandperspective
AT teraamartin mesenchymalstromalcellsforthetreatmentofcriticallimbischemiacontextandperspective
AT verhaarmariannec mesenchymalstromalcellsforthetreatmentofcriticallimbischemiacontextandperspective

Ejemplares similares